Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 146 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psoriasis Chronic Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis

NCT00678470
View directory record Official record
Conditions
Moderate to Severe Psoriasis
Interventions
Intralesional Alefacept
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00292396
View directory record Official record
Conditions
Psoriasis
Interventions
Anti IL-12 monoclonal antibody/ABT-874, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
16
States / cities
San Diego, California • Alpharetta, Georgia • Skokie, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT04785326
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
DMB-3115, Stelara
Drug
Lead sponsor
Dong-A ST Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Norman, Oklahoma • West Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03536884
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab, Secukinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Santa Ana, California • Danbury, Connecticut • Ocala, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00195676
View directory record Official record
Conditions
Psoriasis
Interventions
adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
66
States / cities
Birmingham, Alabama • Buckner 13075 PI, Alabama • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis

NCT02489227
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
CHS-1420, Adalimumab
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
28
States / cities
Phoenix, Arizona • Encino, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional

A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00570986
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Placebo, ABT-874
Drug · Biological
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
1,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
93
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT03025542
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bexley, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

NCT03638258
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
20
States / cities
Beverly Hills, California • Northridge, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01276639
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo/CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Birmingham, Alabama • Irvine, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With Moderate to Severe Psoriasis

NCT01107457
View directory record Official record
Conditions
Psoriasis
Interventions
Ixekizumab, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
31
States / cities
Bakersfield, California • New Haven, Connecticut • Washington D.C., District of Columbia + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

NCT01640951
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque-Type Psoriasis
Interventions
AIN457 150 mg, AIN457 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
28
States / cities
Fresno, California • Pasadena, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

NCT01544595
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
Secukinumab (AIN457), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT05335356
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
Stelara, Bmab1200
Biological
Lead sponsor
Biocon Biologics UK Ltd
Industry
Eligibility
18 Years to 80 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Mayfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326298
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
San Diego, California • West Des Moines, Iowa • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

NCT02581345
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Psoriasis
Interventions
M923, Humira
Biological
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
24
States / cities
Beverly Hills, California • Encino, California • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)

NCT02134210
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Etanercept, CHS-0214
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Not applicable Interventional Results available

Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis

NCT00769184
View directory record Official record
Conditions
Psoriasis
Interventions
Corticosteroid, Placebo, LCD
Drug · Other
Lead sponsor
NeoStrata Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

NCT02969018
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
PF-06700841, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
30
States / cities
Rogers, Arkansas • Anaheim, California • Encinitas, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

NCT02346240
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Etanercept, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate

NCT00673556
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
alefacept, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
16 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
10
States / cities
Irvine, California • Santa Monica, California • Omaha, Nebraska + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Topical CP-690,550 For Chronic Plaque Psoriasis

NCT00678561
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Irvine, California • San Diego, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

NCT01636687
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
Placebo, Secukinumab 150mg, Secukinumab 300mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 21, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

NCT03897075
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis
Interventions
Tildrakizumab, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Encinitas, California • Fountain Valley, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 21, 2026, 2:40 PM EDT